Trial Profile

A Phase 1 Clinical Study of Nemtabrutinib (MK-1026) in Japanese Participants With Hematological Malignancies (BELLWAVE-002)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nemtabrutinib (Primary)
Indications B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Waldenstrom's macroglobulinaemia
Focus Adverse reactions
Acronyms BELLWAVE-002
Sponsors Merck Sharp & Dohme

Most Recent Events

04 Jul 2025 Planned End Date changed from 30 Mar 2026 to 26 Aug 2026.
25 Jan 2024 Status changed from recruiting to active, no longer recruiting.
02 Feb 2023 Planned initiation date (estimated date of first participant enrollment) changed from 30 Jan 2023 to 13 Feb 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com